A phase 1/2 trial of MHB036C in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, active and no longer recruiting.
A Study of MHB036C for Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT06373406 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants enrolled, started 2023-05-26 and due to reach its primary completion in 2025-12. Interventions recorded: MHB036C.
Shares MHB036C, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB036C, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.